CTXR - Citius Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.67
-0.02 (-1.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.69
Open1.73
Bid0.00 x 1400
Ask0.00 x 900
Day's Range1.66 - 1.74
52 Week Range1.12 - 5.49
Volume58,491
Avg. Volume229,438
Market Cap27.052M
Beta (3Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-1.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • PR Newswire19 days ago

    Citius Announces The Publication Of European Patent For Mino-Lok®

    CRANFORD, N.J., Sept. 27, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received official notification from MD Anderson Cancer Center ("MDACC") that the European Patent Application (No. 16806326.1) for Mino-Lok with Enhanced Stability was published (September 12, 2018) under serial number 3370794. This patent which already received a Notice of Allowance from the US Patent and Trademark Office in July of 2018, and which patent was issued by the USPTO earlier this month, will provide and strengthen intellectual property protection for Mino-Lok through November of 2036.

  • PR Newswire21 days ago

    Citius Announces The Issuance Of The Patent On The Advanced Stability Of Mino-Lok® By USPTO

    CRANFORD, N.J., Sept. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") will issue United States Patent Number 10/086,114 entitled "Antimicrobial Solutions with Enhanced Stability" on October 2, 2018.

  • PR Newswire2 months ago

    Citius Pharmaceuticals Successfully Raises $10 Million

    CRANFORD, N.J., Aug. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company completed the largest capital raise in its history of $10 million, and insiders were responsible for supporting 50% of the raise. Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals, invested $1 Million in the Company and Mr. Leonard Mazur, Executive Chairman of Citius Pharmaceuticals invested $4 Million to bring the deal into fruition.

  • PR Newswire2 months ago

    Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Aug. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offering of 7,843,138 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock (the Offering). Each share of Common Stock (or Common Stock equivalent) was sold together with a common warrant to purchase one share of Common Stock at a combined effective price of $1.275 per share and accompanying common warrant.

  • ACCESSWIRE2 months ago

    Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond

    CORAL GABLES, FL / ACCESSWIRE / August 9, 2018 / Healthcare and biotechnology indexes are in the green this morning along with major markets pushing higher. The iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year and has begun turning toward its 52-week high. GT Biopharma (GTBP) is a small cap biotech company with a vast pipeline of treatments.

  • PR Newswire2 months ago

    Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Aug. 9, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering of 7,843,138 shares of its common stock (Common Stock) (or Common Stock equivalent) and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock (the Offering), priced at-the-market. Each share of Common Stock (or Common Stock equivalent) is being sold together with a common warrant to purchase one share of Common Stock at a combined effective price of $1.275 per share and accompanying common warrant.

  • Zacks Small Cap Research3 months ago

    CTRX’s Ph3 Mino-Lok Fills Unmet Need for Catheter-Related Blood Infection Antibiotic

    OTC:ZENO NASDAQ:CTXR Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company focused on the development and commercialization of proprietary formulations of already-approved drugs ...

  • PR Newswire3 months ago

    Citius Announces The Notice Of Allowance From The USPTO On The Advanced Stability Patent Application For Mino-Lok®

    CRANFORD, N.J., July 24, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") has reviewed and examined the patent application US 2017/051373 A1 and that it is allowed for issuance as a patent.

  • PR Newswire3 months ago

    Citius Announces Key Addition to its Scientific Advisory Board

    CRANFORD, N.J., July 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Dr. Lawrence Mermel has accepted a position on the Citius Scientific Advisory Board. Dr. Mermel is Professor of Medicine at the Warren Alpert Medical School of Brown University. Dr. Mermel joins Dr. Isaam Raad, the Chair of MD Anderson Cancer Center's Department of Infectious Diseases (also Chairman of the Citius Scientific Advisory Board), and Dr. Mark Rupp, Professor and Chief of the Division of Infectious Diseases at the University of Nebraska Medical Center.

  • PR Newswire3 months ago

    Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial

    CRANFORD, N.J., July 9, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report on the progress of the Mino-Lok Phase 3 clinical program. The Mino-Lok Phase 3 Trial is planned to enroll 700 patients in 50 participating institutions, all located in the U.S. There will be interim analyses at the 50% and 75% point of the trial as measured by the number of patients treated. Citius reports that as of this past week there are 12 active sites currently enrolling patients including such academic centers as MD Anderson Cancer Center, Henry Ford Health Center, Georgetown University Medical Center, University of Chicago, and others.

  • PR Newswire4 months ago

    Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark

    CRANFORD, N.J., June 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Mino-Lok® is now a registered trademark with the U.S. Patent and Trademark Office.  Citius' Mino-Lok® product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Citius' Mino-Lok® product is intended to salvage the CVC obviating the need to remove and replace the catheter.  This is a recognized unmet medical need. "We are working towards FDA approval and commercialization of Mino-Lok, We are currently conducting a Phase 3 clinical trial and are treating patients with Mino-Lok compared to standard antibiotic lock therapies," said Mr. Myron Holubiak, CEO of Citius.  "Hopefully, we will be able to complete our trial next year and begin the NDA review process.

  • PR Newswire7 months ago

    Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., March 29, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 669,504 shares of its common stock, at a purchase price per share of $2.9850 for gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 669,504 shares of common stock. The warrants have an exercise price of $2.86 per share, will be immediately exercisable, and will expire five and a half years from the issue date.

  • PR Newswire7 months ago

    Citius Reports Progress in Hemorroid Treatment Program

    CRANFORD, N.J., March 6, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (CTXR), a specialty pharmaceutical company, announced that the Company is selecting a higher potency corticosteroid in its steroid/anesthetic topical formulation program for the treatment of hemorrhoids. The original topical preparation, CITI-001, was a combination of hydrocortisone acetate and lidocaine hydrochloride.

  • PR Newswire8 months ago

    Citius Announces Enrollment Of First Patient In The Mino-Lok™ Phase 3 Trial

    CRANFORD, N.J., Feb. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that yesterday the first patient was randomized into the Mino-Lok Phase 3 clinical trial for catheter related bacteremias ("CRBSIs") at the Henry Ford Health System in Detroit, Michigan. Mino-Lok would be the first approved antibiotic lock for the treatment of CRBSIs.

  • PR Newswire8 months ago

    Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias

    SALVAGING INDWELLING CATHETERS IS ESSENTIAL WHEN THERE IS NO VASCULAR ACCESS AND THE PATIENT NEEDS LONG TERM CHRONIC PARENTERAL THERAPY CRANFORD, N.J. , Feb. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, ...

  • PR Newswire8 months ago

    Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

    CRANFORD, N.J. , Jan. 31, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

  • PR Newswire9 months ago

    Citius Pharmaceuticals to Present at Biotech Showcase™ 2018

    CRANFORD, N.J. , Jan. 4, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care ...

  • PR Newswire10 months ago

    Citius Announces $6 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., Dec. 18, 2017 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,280,360 shares of its common stock, at a purchase price per share of $4.6925, for gross proceeds of approximately $6 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 640,180 shares of common stock. The warrants have an exercise price of $4.63 per share, will be immediately exercisable, and will expire five and a half years from the issue date.

  • PR Newswire10 months ago

    Mino-Lok™ Phase 3 Clinical Trial Supplies Shipped to Sites

    CRANFORD, N.J., Dec. 6, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, has announced that clinical trial supplies of Mino-Lok (minocycline/edetate/ethanol) have been sent to the University of Chicago Medical Center, and the Henry Ford Health System in Detroit, the first 2 clinical trial sites for the Mino-Lok phase 3 pivotal trial. When fully recruited, it is planned that there will be 50 participating sites, all located in the U.S.

  • PR Newswire10 months ago

    Citius Pharmaceuticals to Present at the 10th Annual LD Micro Invitational

    LOS ANGELES, Dec. 4, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it will be presenting at the 10th annual LD Micro Invitational on Wednesday, December 6th, at the Luxe Sunset Boulevard Hotel, in Los Angeles, California. Mr. Leonard Mazur, Executive Chairman of Citius, will be giving the presentation and meeting with investors.

  • PR Newswire11 months ago

    Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary

    Use of Mino-Lok™ to disinfect CVCs could avoid patient discomfort while providing an effective alternative in the treatment of Central Line Associated Bloodstream infections (CLABSIs). CRANFORD, N.J. , ...

  • PR Newswirelast year

    Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference

    CRANFORD, N.J. , Oct. 17, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical ...